<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39380982</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-8293</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The journal of allergy and clinical immunology. Global</Title><ISOAbbreviation>J Allergy Clin Immunol Glob</ISOAbbreviation></Journal><ArticleTitle>Case report of secondary T-cell deficiency following the AstraZeneca COVID-19 vaccine.</ArticleTitle><Pagination><StartPage>100339</StartPage><MedlinePgn>100339</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100339</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacig.2024.100339</ELocationID><Abstract><AbstractText>We present a case of secondary T-cell deficiency particularly affecting CD4 T cells, along with the emergence of chronic spontaneous urticaria in a patient following COVID-19 vaccination. The condition was partially managed with omalizumab after initial first-line therapy proved ineffective.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Esmailian</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Sara Laura</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash Lung Sleep Allergy and Immunology, Clayton, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash Health, Clayton, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pumar</LastName><ForeName>Marsus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Monash Health, Clayton, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Allergy Clin Immunol Glob</MedlineTA><NlmUniqueID>9918453488706676</NlmUniqueID><ISSNLinking>2772-8293</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">Secondary T-cell deficiency</Keyword><Keyword MajorTopicYN="N">autoimmune-induced lymphopenia</Keyword><Keyword MajorTopicYN="N">chronic spontaneous urticaria</Keyword><Keyword MajorTopicYN="N">idiopathic total lymphopenia</Keyword><Keyword MajorTopicYN="N">omalizumab</Keyword></KeywordList><CoiStatement>Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39380982</ArticleId><ArticleId IdType="pmc">PMC11459643</ArticleId><ArticleId IdType="doi">10.1016/j.jacig.2024.100339</ArticleId><ArticleId IdType="pii">S2772-8293(24)00135-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sharifian-Dorche M., Bahmanyar M., Sharifian-Dorche A., Mohammadi P., Nomovi M., Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci. 2021;428</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8330139</ArticleId><ArticleId IdType="pubmed">34365148</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton-Chubb D., Schneider D., Freeman E., Kemp W., Roberts S.K. Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine. J Hepatol. 2021;75:1249–1250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219312</ArticleId><ArticleId IdType="pubmed">34171435</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello F., Marino Gammazza A., Dieli F., Conway de Macario E., Macario A.J. Does SARS-CoV-2 trigger stress-induced autoimmunity by molecular mimicry? A hypothesis. J Clin Med. 2020;9:2038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7408943</ArticleId><ArticleId IdType="pubmed">32610587</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-Vila A., Ravichandran N., Selva-O’Callaghan A., Sen P., Nune A., Prithvi Sanjeevkumar Gaur P.S., et al. COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety in idiopathic inflammatory myopathies. Muscle Nerve. 2022;66:426–437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349921</ArticleId><ArticleId IdType="pubmed">35869701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmer S., Bourke J., Nima Mesbah Ardakani. Transient cryoglobulinaemic vasculitis following ChAdOx1 nCoV-19 vaccine. Case Rep. 2022;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9297212</ArticleId><ArticleId IdType="pubmed">35850789</ArticleId></ArticleIdList></Reference><Reference><Citation>de Souza A., Oo W.M., Giri P. Inflammatory demyelinating polyneuropathy after the ChAdOx1 nCoV-19 vaccine may follow a chronic course. J Neurol Sci. 2022;436</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8923716</ArticleId><ArticleId IdType="pubmed">35313224</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheu T.T., Chiang B.L. Lymphopenia, lymphopenia-induced proliferation, and autoimmunity. Int J Mol Sci. 2021;22:4152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8073364</ArticleId><ArticleId IdType="pubmed">33923792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracken S.J., Abraham S., MacLeod A.S. Autoimmune theories of chronic spontaneous urticaria. Front Immunol. 2019;10:627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450064</ArticleId><ArticleId IdType="pubmed">30984191</ArticleId></ArticleIdList></Reference><Reference><Citation>Moutsopoulos H.M. Autoimmune rheumatic diseases: One or many diseases? J Transl Autoimmun. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8716565</ArticleId><ArticleId IdType="pubmed">35005593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>